ATXS RSI Chart
Last 7 days
-1.8%
Last 30 days
-9.5%
Last 90 days
-31.6%
Trailing 12 Months
-24.0%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | morabito christopher | sold | -135,939 | 13.5939 | -10,000 | chief medical officer |
Apr 01, 2024 | morabito christopher | acquired | 38,700 | 3.87 | 10,000 | chief medical officer |
Feb 01, 2024 | perceptive advisors llc | bought | 29,999,500 | 12.09 | 2,481,350 | - |
Jan 29, 2024 | morabito christopher | sold | -102,552 | 11.147 | -9,200 | chief medical officer |
Jan 29, 2024 | morabito christopher | acquired | 35,604 | 3.87 | 9,200 | chief medical officer |
Jan 26, 2024 | morabito christopher | sold | -8,812 | 11.015 | -800 | chief medical officer |
Jan 26, 2024 | morabito christopher | acquired | 3,096 | 3.87 | 800 | chief medical officer |
Dec 21, 2023 | perceptive advisors llc | bought | 4,588,000 | 6.2 | 740,000 | - |
Oct 16, 2023 | perceptive advisors llc | bought | 7,000,000 | 6.514 | 1,074,610 | - |
Dec 19, 2022 | perceptive advisors llc | bought | 10,000,000 | 11.01 | 908,265 | - |
Which funds bought or sold ATXS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | new | - | 12,445,300 | 12,445,300 | 0.32% |
May 17, 2024 | Ikarian Capital, LLC | reduced | -62.46 | -898,347 | 1,980,170 | 0.22% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -15.59 | 168,366 | 476,158 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -7.92 | 28,754 | 70,572 | -% |
May 16, 2024 | Tidal Investments LLC | new | - | 1,663,660 | 1,663,660 | 0.03% |
May 15, 2024 | Voya Investment Management LLC | added | 15.76 | 117,364 | 222,019 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -63.55 | -245,545 | 494,047 | 0.01% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | added | 61.97 | 60,498,600 | 91,249,900 | 1.58% |
May 15, 2024 | Royal Bank of Canada | reduced | -91.11 | -80,000 | 16,000 | -% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | added | 38.4 | 921,827 | 1,521,790 | 0.11% |
Unveiling Astria Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Astria Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Astria Therapeutics, Inc. News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 48.7% | 379 | 255 | 194 | 207 | 218 | 231 | 120 | 105 | 115 | 128 | 135 | 141 | 149 | 47.00 | 57.00 | 57.00 | 59.00 | 42.00 | 44.00 | 49.00 | 54.00 |
Current Assets | 49.2% | 375 | 251 | 191 | 204 | 215 | 228 | 118 | 104 | 114 | 127 | 135 | 140 | 148 | 46.00 | 56.00 | 56.00 | 57.00 | 39.00 | 43.00 | 47.00 | 53.00 |
Cash Equivalents | -1.9% | 172 | 176 | 120 | 134 | 202 | 21.00 | 46.00 | 30.00 | 47.00 | 87.00 | 132 | 140 | 147 | 25.00 | 53.00 | 52.00 | 13.00 | 10.00 | 18.00 | 10.00 | 12.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 |
Liabilities | -4.1% | 11.00 | 12.00 | 9.00 | 7.00 | 7.00 | 9.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 | 4.00 | 9.00 | 7.00 | 8.00 | 6.00 | 5.00 | 6.00 | 6.00 | 5.00 | 5.00 |
Current Liabilities | -4.1% | 11.00 | 12.00 | 9.00 | 7.00 | 7.00 | 9.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 |
Shareholder's Equity | 51.3% | 368 | 243 | 184 | 200 | 211 | 221 | 113 | 99.00 | 110 | 122 | 130 | 137 | 330 | 41.00 | 49.00 | 0.00 | 54.00 | 36.00 | 38.00 | 254 | 253 |
Retained Earnings | -3.4% | -600 | -580 | -549 | -531 | -518 | -507 | -494 | -482 | -471 | -455 | -446 | -438 | -431 | -260 | -251 | -241 | -231 | -223 | -216 | -210 | -203 |
Additional Paid-In Capital | 19.8% | 873 | 728 | 638 | 636 | 635 | 633 | 511 | 486 | 484 | 482 | 480 | 475 | 330 | 302 | 301 | 292 | 285 | 259 | 255 | 254 | 253 |
Shares Outstanding | 33.8% | 55.00 | 41.00 | 28.00 | 28.00 | 28.00 | 28.00 | 14.00 | 13.00 | 13.00 | 13.00 | 8.00 | 5.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 280 | - | - | - | 26.00 | - | - | - | 130 | - | - | - | 101 | - | - | - | 73.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 36.9% | -19,094 | -30,238 | -14,258 | -10,696 | -13,253 | -10,664 | -10,249 | -10,061 | -12,559 | -6,286 | -7,749 | -7,400 | -8,716 | -8,061 | -9,969 | -7,466 | -6,989 | -7,770 | -6,474 | -5,738 | -6,587 |
Share Based Compensation | 33.1% | 2,754 | 2,069 | 1,694 | 1,331 | 1,220 | 1,073 | 1,155 | 1,117 | 1,209 | 972 | 1,010 | 1,014 | 366 | 305 | 375 | - | - | 285 | 378 | 441 | 408 |
Cashflow From Investing | -6161.5% | -126,231 | -2,016 | -4.00 | -57,920 | 194,992 | -135,180 | 1,950 | -6,800 | -27,099 | -39,000 | - | - | 26,445 | -20,010 | 2,000 | 39,742 | -15,432 | -3,504 | 13,651 | 3,509 | -17,738 |
Cashflow From Financing | 61.2% | 141,807 | 87,978 | 110 | 273 | 37.00 | 120,397 | - | - | - | 17.00 | 6.00 | - | 104,261 | 31.00 | 8,940 | 6,265 | 25,624 | 3,772 | 973 | 192 | 20,683 |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 15,726 | $ 8,033 |
General and administrative | 8,424 | 5,460 |
Total operating expenses | 24,150 | 13,493 |
Loss from operations | (24,150) | (13,493) |
Other income (expense): | ||
Interest and investment income | 4,241 | 2,321 |
Other expense, net | (19) | (16) |
Total other income, net | 4,222 | 2,305 |
Net loss | $ (19,928) | $ (11,188) |
Net loss per share attributable to common shareholders - basic | $ (0.38) | $ (0.40) |
Net loss per share attributable to common shareholders - diluted | $ (0.38) | $ (0.40) |
Weighted-average common shares outstanding used in net loss per share - basic | 52,294,765 | 27,944,458 |
Weighted-average common shares outstanding used in net loss per share - diluted | 52,294,765 | 27,944,458 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 172,012 | $ 175,530 |
Short-term investments | 197,895 | 71,000 |
Prepaid expenses and other current assets | 4,614 | 4,412 |
Total current assets | 374,521 | 250,942 |
Right-of-use asset | 210 | 363 |
Other assets | 4,076 | 3,361 |
Total assets | 378,807 | 254,666 |
Current liabilities: | ||
Accounts payable | 862 | 1,513 |
Accrued expenses | 10,042 | 9,708 |
Current portion of operating lease liabilities | 168 | 329 |
Total current liabilities | 11,072 | 11,550 |
Total liabilities | 11,072 | 11,550 |
Commitments (Note 6) | ||
Stockholders' equity: | ||
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 54,903,061 and 41,034,797 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 55 | 41 |
Additional paid-in capital | 872,832 | 728,285 |
Accumulated other comprehensive loss | (14) | |
Accumulated deficit | (600,462) | (580,534) |
Total stockholders' equity | 367,735 | 243,116 |
Total liabilities and stockholders' equity | 378,807 | 254,666 |
Preferred stock | ||
Stockholders' equity: | ||
Preferred stock | ||
Series X redeemable convertible preferred stock | ||
Stockholders' equity: | ||
Preferred stock | $ 95,324 | $ 95,324 |